Log In
BCIQ
Print this Print this
 

Alprolix, eftrenonacog alfa (rFIXFc)

Also known as: Long Acting rFactor lX (FIXFc) (formerly FIX:Fc)

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionRecombinant fusion protein consisting of human coagulation Factor IX attached to the Fc domain of human IgG1
Molecular Target Factor IX
Mechanism of ActionFactor IX replacement
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in patients with hemophilia B; Treat hemophilia B; Treat hemophilia B in pediatric patients
Regulatory Designation U.S. - Orphan Drug (Treat hemophilia B);
U.S. - Undisclosed Review (Treat hemophilia B);
EU - Orphan Drug (Treat hemophilia B);
Japan - Standard Review (Treat and prevent bleeding in patients with hemophilia B);
Australia - Orphan Drug (Treat and prevent bleeding in patients with hemophilia B);
Australia - Standard Review (Treat and prevent bleeding in patients with hemophilia B)
PartnerSwedish Orphan Biovitrum AB;
UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/03/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today